Atossa Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ATOS and other ETFs, options, and stocks.

About ATOS

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. 

CEO
Steven C. Quay
CEOSteven C. Quay
Employees
15
Employees15
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
2008
Founded2008
Employees
15
Employees15

ATOS Key Statistics

Market cap
83.70M
Market cap83.70M
Price-Earnings ratio
-2.78
Price-Earnings ratio-2.78
Dividend yield
Dividend yield
Average volume
1.48M
Average volume1.48M
High today
$0.6676
High today$0.6676
Low today
$0.63
Low today$0.63
Open price
$0.66
Open price$0.66
Volume
893.29K
Volume893.29K
52 Week high
$1.29
52 Week high$1.29
52 Week low
$0.551
52 Week low$0.551

Stock Snapshot

As of today, Atossa Therapeutics(ATOS) shares are valued at $0.63. The company's market cap stands at 83.7M, with a P/E ratio of -2.78.

During the trading session on 2026-01-09, Atossa Therapeutics(ATOS) shares reached a daily high of $0.67 and a low of $0.63. At a current price of $0.63, the stock is 0.0% higher than the low and still -5.6% under the high.

Trading volume for Atossa Therapeutics(ATOS) stock has reached 893.29K, versus its average volume of 1.48M.

Over the past 52 weeks, Atossa Therapeutics(ATOS) stock has traded between a high of $1.29 and a low of $0.55.

Over the past 52 weeks, Atossa Therapeutics(ATOS) stock has traded between a high of $1.29 and a low of $0.55.

ATOS News

TipRanks 12h
Atossa Therapeutics outlines strategy for lead-Endoxifen program

Claim 70% Off TipRanks Premium The latest announcement is out from Atossa Therapeutics ( (ATOS) ). In a recent Form 8-K, Atossa Therapeutics furnished a corpo...

TipRanks 4d
Atossa Therapeutics receives “Study May Proceed” letter for breast cancer study

Atossa Therapeutics (ATOS) announced that the U.S. FDA issued a “Study May Proceed” letter for the company’s study in metastatic breast cancer which was the sub...

People also own

Based on the portfolios of people who own ATOS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.